By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has issued a warning letter to Beckman Coulter citing issues it identified at the company's Miami facility.

In a letter dated Nov. 1 and posted this week on FDA's website, the agency said that it had found that Class I and II in vitro diagnostic products manufactured at the site were "adulterated … and not in conformity with the Current Good Manufacturing Practice requirements" as defined by federal regulations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.